1364. Efficacy of Omadacycline Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials

BACKGROUND: Omadacycline (OMC) is a once-daily agent with IV and oral formulations. One Phase 3 trial for community-acquired bacterial pneumonia (CABP; OPTIC) and two Phase 3 trials for acute bacterial skin and skin structure infections (ABSSSI; OASIS-1 and OASIS-2) were completed. OMC and comparato...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Mendes, Rodrigo E, Castanheira, Mariana, Armstrong, Eliana S, Steenbergen, Judith N, Flamm, Robert K
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2018
Assuntos:
Abstracts
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252834/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1195
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares